II期临床-话题@MedSci

#II期临床#

478篇内容 | 2575人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524647, encodeId=e2a8152464ec2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=PLOS ONE：天花疫苗MVA的III期临床试验结果, objectType=article, longId=135459, objectId=662a13545945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=662a13545945, replyNumber=0, likeNumber=63, createdTime=2018-04-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=662a13545945, moduleTitle=PLOS ONE：天花疫苗MVA的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=662a13545945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524646, encodeId=40c0152464651, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=J Clin Oncol：II期临床显示Crizotinib在东亚患者中具有抗肿瘤活性, objectType=article, longId=133918, objectId=05b213391822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05b213391822, replyNumber=0, likeNumber=62, createdTime=2018-04-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05b213391822, moduleTitle=J Clin Oncol：II期临床显示Crizotinib在东亚患者中具有抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05b213391822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524645, encodeId=8620152464591, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=EUR J Cancer：纳米紫杉醇联合雷莫芦单抗治疗胃癌的II期临床研究, objectType=article, longId=130890, objectId=c161130890e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c161130890e4, replyNumber=0, likeNumber=0, createdTime=2018-03-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c161130890e4, moduleTitle=EUR J Cancer：纳米紫杉醇联合雷莫芦单抗治疗胃癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c161130890e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524644, encodeId=4b941524644e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究, objectType=article, longId=130729, objectId=edaa130e2993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edaa130e2993, replyNumber=0, likeNumber=49, createdTime=2018-02-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edaa130e2993, moduleTitle=EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edaa130e2993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524643, encodeId=27c015246432b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Mithra宣布Donesta的II期临床试验已经完成, objectType=article, longId=128113, objectId=70ca12811316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ca12811316, replyNumber=0, likeNumber=72, createdTime=2018-01-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ca12811316, moduleTitle=Mithra宣布Donesta的II期临床试验已经完成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ca12811316)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524642, encodeId=ec3515246426c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Teva的皮下哮喘药物在III期临床试验中失败, objectType=article, longId=127488, objectId=74dd12e488a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74dd12e488a0, replyNumber=0, likeNumber=78, createdTime=2018-01-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74dd12e488a0, moduleTitle=Teva的皮下哮喘药物在III期临床试验中失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74dd12e488a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524641, encodeId=40cf152464184, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败, objectType=article, longId=126123, objectId=8fa3126123fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa3126123fa, replyNumber=0, likeNumber=59, createdTime=2018-01-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa3126123fa, moduleTitle=JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa3126123fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524640, encodeId=45b815246403f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究, objectType=article, longId=125930, objectId=85ca1259307a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ca1259307a, replyNumber=0, likeNumber=52, createdTime=2018-01-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ca1259307a, moduleTitle=Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85ca1259307a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524639, encodeId=6b16152463968, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验, objectType=article, longId=125219, objectId=0ec912521937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec912521937, replyNumber=0, likeNumber=58, createdTime=2018-01-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec912521937, moduleTitle=EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ec912521937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524638, encodeId=624d152463851, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验, objectType=article, longId=125185, objectId=de17125185b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de17125185b2, replyNumber=0, likeNumber=68, createdTime=2018-01-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de17125185b2, moduleTitle=EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de17125185b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524637, encodeId=9b6f152463e58, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=EUR J Cancer：舒尼替尼治疗局部晚期或转移性、间变性甲状腺髓质癌的多中心II期临床试验, objectType=article, longId=124996, objectId=11e112499612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11e112499612, replyNumber=0, likeNumber=54, createdTime=2017-12-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11e112499612, moduleTitle=EUR J Cancer：舒尼替尼治疗局部晚期或转移性、间变性甲状腺髓质癌的多中心II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11e112499612)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524636, encodeId=bb64152463623, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验, objectType=article, longId=124749, objectId=622e124e49ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=622e124e49ed, replyNumber=0, likeNumber=54, createdTime=2017-12-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=622e124e49ed, moduleTitle=EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=622e124e49ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524635, encodeId=c7571524635df, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, objectType=article, longId=124481, objectId=c81c12448125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c81c12448125, replyNumber=0, likeNumber=54, createdTime=2017-12-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c81c12448125, moduleTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c81c12448125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524634, encodeId=c127152463418, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验, objectType=article, longId=124108, objectId=397812410839, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397812410839, replyNumber=0, likeNumber=58, createdTime=2017-12-22, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397812410839, moduleTitle=EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397812410839)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524633, encodeId=a7d415246337e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验, objectType=article, longId=124106, objectId=bed9124106d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bed9124106d6, replyNumber=0, likeNumber=77, createdTime=2017-12-22, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bed9124106d6, moduleTitle=EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bed9124106d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524632, encodeId=4c501524632f0, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著, objectType=article, longId=123310, objectId=7e0a123310a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e0a123310a5, replyNumber=0, likeNumber=19, createdTime=2017-12-15, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e0a123310a5, moduleTitle=【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e0a123310a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524631, encodeId=96c31524631c2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=【2017 ASH】II期临床结果表明伊布替尼联合Venetoclax 对复发难治性以及遗传高风险CLL患者效果显著, objectType=article, longId=122976, objectId=1b1f1229e69f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b1f1229e69f, replyNumber=0, likeNumber=47, createdTime=2017-12-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b1f1229e69f, moduleTitle=【2017 ASH】II期临床结果表明伊布替尼联合Venetoclax 对复发难治性以及遗传高风险CLL患者效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b1f1229e69f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524630, encodeId=473215246300a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性, objectType=article, longId=122745, objectId=1ede122e4567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ede122e4567, replyNumber=0, likeNumber=19, createdTime=2017-12-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ede122e4567, moduleTitle=【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ede122e4567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524629, encodeId=54891524629b7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%, objectType=article, longId=120485, objectId=e3de120485e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3de120485e7, replyNumber=0, likeNumber=71, createdTime=2017-11-19, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3de120485e7, moduleTitle=诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3de120485e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524628, encodeId=b1f615246287e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：Nusinersen治疗婴儿脊髓性肌萎缩症III期临床结果, objectType=article, longId=118500, objectId=27dc1185009a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27dc1185009a, replyNumber=0, likeNumber=62, createdTime=2017-11-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27dc1185009a, moduleTitle=NEJM：Nusinersen治疗婴儿脊髓性肌萎缩症III期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27dc1185009a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

PLOS ONE：天花疫苗MVA的III期临床试验结果

2018-04-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

J Clin Oncol：II期临床显示Crizotinib在东亚患者中具有抗肿瘤活性

2018-04-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

EUR J Cancer：纳米紫杉醇联合雷莫芦单抗治疗胃癌的II期临床研究

2018-03-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究

2018-02-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Mithra宣布Donesta的II期临床试验已经完成

2018-01-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Teva的皮下哮喘药物在III期临床试验中失败

2018-01-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败

2018-01-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究

2018-01-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验

2018-01-02

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验

2018-01-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

EUR J Cancer：舒尼替尼治疗局部晚期或转移性、间变性甲状腺髓质癌的多中心II期临床试验

2017-12-30

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验

2017-12-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）

2017-12-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验

2017-12-22

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验

2017-12-22

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著

2017-12-15

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

【2017 ASH】II期临床结果表明伊布替尼联合Venetoclax 对复发难治性以及遗传高风险CLL患者效果显著

2017-12-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性

2017-12-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%

2017-11-19

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：Nusinersen治疗婴儿脊髓性肌萎缩症III期临床结果

2017-11-04

科室
- - 订阅+
  - 更多科室
工具
服务